Dr. Sucharit S. Joshi, M.D.
Nephrology (Kidney) (Nephrology Physician)
- Medicare participating
At a glance
- Medical school
- Icahn School of Medicine at Mount Sinai (2005)
- Years since graduation
- 21
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 521
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Medical school: Icahn School of Medicine at Mount Sinai
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nephrology Physician primary
NH license 15305 · ME license 018840
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Wentworth-Douglass Hospital Dover, NH
- Portsmouth Regional Hospital Portsmouth, NH
- Exeter Hospital Inc Exeter, NH
- York Hospital York, ME
- Frisbie Memorial Hospital Rochester, NH
Medical groups
- Seacoast Kidney and Hypertension Specialists, P.l.l.c. (7 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 521
- Services billed
- 1,559
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 923 | 254 |
| Established patient office or other outpatient visit, 30-39 minutes | 265 | 192 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 259 | 130 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 174 | 163 |
| Hemodialysis procedure with physician evaluation | 100 | 48 |
| Established patient office or other outpatient visit, 20-29 minutes | 70 | 70 |
| Established patient office or other outpatient visit, 40-54 minutes | 65 | 42 |
| Home dialysis services per month (20 years or older) | 43 | 14 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 42 | 18 |
| New patient office or other outpatient visit, 45-59 minutes | 34 | 34 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 4 companies. The companies reported $521,858 in research payments for these studies, mostly to the institutions running them.
- A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease
Boehringer Ingelheim International GmbH - Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
Csl Behring · Recruiting · NCT05485961 - A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease
Boehringer Ingelheim Pharma GmbH & Co.kg - Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)
Alnylam Pharmaceuticals Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.